ACTG1P22: A Drug Target / Disease Biomarker (G100131953)

Target Name: ACTG1P22

NCBI ID: G100131953

ACTG1P22

Other Name(s): actin gamma 1 pseudogene 22 | Actin gamma 1 pseudogene 22

ACTG1P22: A Drug Target / Disease Biomarker

ACTG1P22 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the actinin family, which is known for their role in cell signaling and cytoskeletal organization.

One of the key functions of ACTG1P22 is its role in regulating the formation of new blood vessels in the brain. This protein is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply the growing brain with oxygen and nutrients.

In addition to its role in blood vessel formation, ACTG1P22 is also involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells die and are removed from the body.

ACTG1P22 has also been shown to be involved in the regulation of cellular signaling pathways that are important for brain development and function. For example, it has been shown to play a role in the regulation of the Wnt signaling pathway, which is important for the development and maintenance of brain neural networks.

In conclusion, ACTG1P22 is a protein that is involved in a variety of important functions in the brain, including blood vessel formation, cell survival and proliferation, and cellular signaling pathways. As a drug target or biomarker, ACTG1P22 may be useful for the development of new treatments for a variety of neurological and psychiatric disorders.

Protein Name: Actin Gamma 1 Pseudogene 22

The "ACTG1P22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTG1P22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets